CHRNB4 and acute myeloid leukemia: Clinically, <i>CHRNB4</i> downregulation correlates with shortened overall survival and diminished response to venetoclax.<h4>Conclusions</h4>Our findings implicate the NLRI pathway in venetoclax resistance and identify CHRNB4 as a robust prognostic indicator and a promising therapeutic target for developing next-generation AML strategies.